A Phase 1 Study Evaluating AMG 232 in Advanced Solid Tumors or Multiple Myeloma

Summary

First in human, open-label, sequential dose escalation and expansion study of AMG 232 in subjects with advanced solid tumors or multiple myeloma

Timeline

Start

2012-12-27

Primary completion

2017-03-15

Completion

2017-09-25

Drugs

Indications